Clinical experiment designed to assess clinical efficacy targeting PSP in human. Primary outcome: Validate Levodopa Response Determinants in PSP — Biomarker-Guided Prediction Study
Description
Levodopa Response Determinants in PSP — Biomarker-Guided Prediction Study
Background and Rationale
Progressive supranuclear palsy (PSP) is a tauopathy characterized by variable motor symptoms and poor levodopa responsiveness, distinguishing it from Parkinson's disease. However, clinical heterogeneity exists, with some PSP patients showing modest levodopa benefits while others demonstrate no response. This variability may reflect differences in underlying dopaminergic system integrity and pathological burden. Current diagnostic approaches cannot predict levodopa responsiveness, leading to inefficient treatment trials and delayed optimization of therapeutic strategies. This biomarker-guided prediction study addresses a critical clinical need by developing objective measures to identify PSP patients most likely to benefit from levodopa therapy. The study employs a comprehensive biomarker approach combining dopamine transporter SPECT imaging (DaTscan), cerebrospinal fluid analysis, and standardized levodopa challenge testing....
Levodopa Response Determinants in PSP — Biomarker-Guided Prediction Study
Background and Rationale
Progressive supranuclear palsy (PSP) is a tauopathy characterized by variable motor symptoms and poor levodopa responsiveness, distinguishing it from Parkinson's disease. However, clinical heterogeneity exists, with some PSP patients showing modest levodopa benefits while others demonstrate no response. This variability may reflect differences in underlying dopaminergic system integrity and pathological burden. Current diagnostic approaches cannot predict levodopa responsiveness, leading to inefficient treatment trials and delayed optimization of therapeutic strategies. This biomarker-guided prediction study addresses a critical clinical need by developing objective measures to identify PSP patients most likely to benefit from levodopa therapy. The study employs a comprehensive biomarker approach combining dopamine transporter SPECT imaging (DaTscan), cerebrospinal fluid analysis, and standardized levodopa challenge testing. DaTscan will quantify nigrostriatal dopamine terminal integrity, while CSF biomarkers including alpha-synuclein, tau species, and neurofilament light chain will assess neurodegeneration patterns. The innovation lies in integrating multiple biomarker modalities to create a predictive algorithm for levodopa responsiveness in PSP. This prospective cohort study will establish baseline biomarker profiles, followed by standardized levodopa challenges with objective motor assessments using UPDRS-III scores and quantitative movement analysis. The significance extends beyond PSP management, potentially informing broader principles of precision medicine in parkinsonian disorders and advancing understanding of dopaminergic system preservation across neurodegenerative conditions.
This experiment directly tests predictions arising from the following hypotheses:
Smartphone-Detected Motor Variability Correction
Noradrenergic-Tau Propagation Blockade
HCN1-Mediated Resonance Frequency Stabilization Therapy
Phase 1 (Weeks 1-2): Recruit 120 PSP patients meeting MDS-PSP criteria and 40 healthy controls. Obtain informed consent and perform comprehensive baseline assessments including MDS-UPDRS-III, PSP rating scale, and cognitive evaluations. Phase 2 (Weeks 3-4): Conduct DaTscan imaging using 123I-ioflupane injection (185 MBq) with SPECT acquisition 3-6 hours post-injection. Calculate striatal binding ratios using semi-automated software. Perform lumbar puncture within 7 days, collecting 15ml CSF in polypropylene tubes. Measure CSF alpha-synuclein, total tau, phospho-tau181, phospho-tau217, neurofilament light chain, and SNCA using electrochemiluminescence immunoassays. Phase 3 (Weeks 5-6): Administer standardized levodopa challenge test. Patients undergo 12-hour medication washout, then receive 250mg levodopa/25mg carbidopa. Assess UPDRS-III scores at baseline, 60, 120, and 180 minutes post-dose. Perform quantitative gait analysis and finger-tapping assessments. Phase 4 (Weeks 7-8): Statistical analysis using machine learning algorithms to develop predictive models. Primary endpoint: ≥20% improvement in UPDRS-III at 60 minutes post-levodopa. Secondary analyses include correlation matrices between biomarkers and response magnitude, ROC curve analysis for predictive accuracy, and validation using bootstrap resampling methods.
Expected Outcomes
PSP patients with DaTscan binding ratios >1.5 in caudate nucleus will demonstrate 65-75% likelihood of positive levodopa response versus 15-25% in those with ratios <1.0 (p<0.001)
CSF alpha-synuclein levels >1200 pg/ml combined with neurofilament light <2000 pg/ml will predict levodopa responsiveness with 78% sensitivity and 82% specificity
Multi-biomarker predictive model will achieve area under ROC curve of 0.85-0.92 for identifying levodopa responders, significantly outperforming clinical assessment alone (AUC 0.62)
Levodopa responders will show 28±12% mean improvement in UPDRS-III scores compared to 5±8% in non-responders, with effect size (Cohen's d) of 2.1-2.4
Preserved striatal dopamine terminal density will correlate with CSF tau/alpha-synuclein ratio (r=-0.68, p<0.001), supporting distinct pathophysiological subgroups
Baseline biomarker panel will predict sustained levodopa benefit at 6-month follow-up with 71% positive predictive value and 89% negative predictive value
Success Criteria
• Achievement of primary endpoint: statistically significant association (p<0.01) between baseline biomarker composite score and levodopa response magnitude
• Predictive model demonstrates area under ROC curve ≥0.80 with cross-validation accuracy >75% for identifying levodopa responders
• Identification of optimal biomarker cut-points yielding sensitivity ≥70% and specificity ≥75% for clinical decision-making
• Successful recruitment and retention of ≥90% of target sample size (108/120 PSP patients) with complete biomarker and outcome data
• Validation of biomarker-clinical correlation with effect sizes ≥0.8 for primary associations and confidence intervals excluding null hypothesis
• Development of clinically applicable algorithm with ≥80% accuracy in independent validation subset, suitable for implementation in clinical practice
TARGET GENE
PSP
MODEL SYSTEM
human
ESTIMATED COST
$5,460,000
TIMELINE
45 months
PATHWAY
N/A
SOURCE
wiki
PRIMARY OUTCOME
Validate Levodopa Response Determinants in PSP — Biomarker-Guided Prediction Study
Phase 1 (Weeks 1-2): Recruit 120 PSP patients meeting MDS-PSP criteria and 40 healthy controls. Obtain informed consent and perform comprehensive baseline assessments including MDS-UPDRS-III, PSP rating scale, and cognitive evaluations. Phase 2 (Weeks 3-4): Conduct DaTscan imaging using 123I-ioflupane injection (185 MBq) with SPECT acquisition 3-6 hours post-injection. Calculate striatal binding ratios using semi-automated software. Perform lumbar puncture within 7 days, collecting 15ml CSF in polypropylene tubes. Measure CSF alpha-synuclein, total tau, phospho-tau181, phospho-tau217, neurofilament light chain, and SNCA using electrochemiluminescence immunoassays. Phase 3 (Weeks 5-6): Administer standardized levodopa challenge test.
...
Phase 1 (Weeks 1-2): Recruit 120 PSP patients meeting MDS-PSP criteria and 40 healthy controls. Obtain informed consent and perform comprehensive baseline assessments including MDS-UPDRS-III, PSP rating scale, and cognitive evaluations. Phase 2 (Weeks 3-4): Conduct DaTscan imaging using 123I-ioflupane injection (185 MBq) with SPECT acquisition 3-6 hours post-injection. Calculate striatal binding ratios using semi-automated software. Perform lumbar puncture within 7 days, collecting 15ml CSF in polypropylene tubes. Measure CSF alpha-synuclein, total tau, phospho-tau181, phospho-tau217, neurofilament light chain, and SNCA using electrochemiluminescence immunoassays. Phase 3 (Weeks 5-6): Administer standardized levodopa challenge test. Patients undergo 12-hour medication washout, then receive 250mg levodopa/25mg carbidopa. Assess UPDRS-III scores at baseline, 60, 120, and 180 minutes post-dose. Perform quantitative gait analysis and finger-tapping assessments. Phase 4 (Weeks 7-8): Statistical analysis using machine learning algorithms to develop predictive models. Primary endpoint: ≥20% improvement in UPDRS-III at 60 minutes post-levodopa. Secondary analyses include correlation matrices between biomarkers and response magnitude, ROC curve analysis for predictive accuracy, and validation using bootstrap resampling methods.
Expected Outcomes
PSP patients with DaTscan binding ratios >1.5 in caudate nucleus will demonstrate 65-75% likelihood of positive levodopa response versus 15-25% in those with ratios <1.0 (p<0.001)
CSF alpha-synuclein levels >1200 pg/ml combined with neurofilament light <2000 pg/ml will predict levodopa responsiveness with 78% sensitivity and 82% specificity
Multi-biomarker predictive model will achieve area under ROC curve of 0.85-0.92 for identifying levodopa responders, significantly outperforming clinical assessment alone (AUC 0.62)
Levodopa responders will show 28±12% mean improvement in UPDRS-III s
...
PSP patients with DaTscan binding ratios >1.5 in caudate nucleus will demonstrate 65-75% likelihood of positive levodopa response versus 15-25% in those with ratios <1.0 (p<0.001)
CSF alpha-synuclein levels >1200 pg/ml combined with neurofilament light <2000 pg/ml will predict levodopa responsiveness with 78% sensitivity and 82% specificity
Multi-biomarker predictive model will achieve area under ROC curve of 0.85-0.92 for identifying levodopa responders, significantly outperforming clinical assessment alone (AUC 0.62)
Levodopa responders will show 28±12% mean improvement in UPDRS-III scores compared to 5±8% in non-responders, with effect size (Cohen's d) of 2.1-2.4
Preserved striatal dopamine terminal density will correlate with CSF tau/alpha-synuclein ratio (r=-0.68, p<0.001), supporting distinct pathophysiological subgroups
Baseline biomarker panel will predict sustained levodopa benefit at 6-month follow-up with 71% positive predictive value and 89% negative predictive value
Success Criteria
• Achievement of primary endpoint: statistically significant association (p<0.01) between baseline biomarker composite score and levodopa response magnitude
• Predictive model demonstrates area under ROC curve ≥0.80 with cross-validation accuracy >75% for identifying levodopa responders
• Identification of optimal biomarker cut-points yielding sensitivity ≥70% and specificity ≥75% for clinical decision-making
• Successful recruitment and retention of ≥90% of target sample size (108/120 PSP patients) with complete biomarker and outcome data
• Validation of biomarker-clinical correlatio
...
• Achievement of primary endpoint: statistically significant association (p<0.01) between baseline biomarker composite score and levodopa response magnitude
• Predictive model demonstrates area under ROC curve ≥0.80 with cross-validation accuracy >75% for identifying levodopa responders
• Identification of optimal biomarker cut-points yielding sensitivity ≥70% and specificity ≥75% for clinical decision-making
• Successful recruitment and retention of ≥90% of target sample size (108/120 PSP patients) with complete biomarker and outcome data
• Validation of biomarker-clinical correlation with effect sizes ≥0.8 for primary associations and confidence intervals excluding null hypothesis
• Development of clinically applicable algorithm with ≥80% accuracy in independent validation subset, suitable for implementation in clinical practice